Page last updated: 2024-11-05

3,7-dimethyloctan-1-ol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3,7-dimethyloctan-1-ol: penetration enhancer for transdermal delivery of 5-fluorouracil; ligand for odorant-binding protein; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID7792
CHEMBL ID3181881
CHEBI ID195928
SCHEMBL ID27965
MeSH IDM0175466

Synonyms (80)

Synonym
1333-49-9
1-octanol, dimethyl-
1-octanol, 3,7-dimethyl-, ( )-
1-octanol, 3,7-dimethyl-, (.+/-.)-
nsc 18917
dimethyl octanol
brn 1719638
3,7-dimethyloctan-1-ol
ai3-11222
fema no. 2391
einecs 203-374-5
106-21-8
dimethyloctanol
citronellol, dihydro-
nsc-18917
wln: q2y1 & 3y1 & 1
geraniol, perhydro-
pelargol
tetrahydrogeraniol
nsc18917
2,6-dimethyl-8-octanol
3,7-dimethyl-1-octanol
geraniol tetrahydride
1-octanol,7-dimethyl-
dihydrocitronellol
geraniol, tetrahydro-
perhydrogeraniol
1-octanol, 3,7-dimethyl-, (r)-
1-octanol, 3,7-dimethyl-
3,7-dimethyl-1-octanol, >=98%, fcc, fg
3,7-dimethyl-1-octanol, >=98%
D1442
CHEBI:195928
(r)-dihydrocitronellol
AKOS004905708
NCGC00248230-01
tox21_300961
dtxsid5044360 ,
cas-106-21-8
dtxcid3024360
NCGC00254863-01
dimethyloctan-2-ol
FT-0676003
ec 203-374-5
dpy9k1927c ,
1-01-00-00214 (beilstein handbook reference)
unii-dpy9k1927c
FT-0625148
1-octanol,3,7-dimethyl-, (3s)-
(+/-)-3,7-dimethyloctanol
3,7-dimethyl-octan-1-ol
3,7-dimethyloctanol
3,7-dimethyloctan-ol
SCHEMBL27965
3,7-dimethyl-1-octanol [fcc]
3,7-dimethyl-1-octanol, (+/-)-
3,7-dimethyl-1-octanol [fhfi]
dihydrocitronellol [inci]
3,7-dimethyl-1-octanol, dl-
tetrahydro geraniol
W-109392
CHEMBL3181881
LMFA05000565
mfcd00002936
perhydro-geraniol
dihydro-citronellol
3,7-dimethyl-(s)-1-octanol
3,7-dimethyl-(r)-1-octanol
3,7-dimethyl-(.+/-.)-1-octanol
tetrahydro-geraniol
dimethyl-1-octanol
tetrahydrogeraniol;3,7-dimethyl-1-octanol
E77185
Q27276531
mfcd27965646
SY275110
YSZC1729
CS-W010892
EN300-7698205
HY-W010176
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aliphatic alcoholAn alcohol derived from an aliphatic compound.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLI family zinc finger 3Homo sapiens (human)Potency45.02730.000714.592883.7951AID1259369; AID1259392
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency54.48270.000657.913322,387.1992AID1259377
progesterone receptorHomo sapiens (human)Potency0.24340.000417.946075.1148AID1346784
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency76.95880.003041.611522,387.1992AID1159553
retinoid X nuclear receptor alphaHomo sapiens (human)Potency30.03140.000817.505159.3239AID1159527; AID1159531
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency48.96620.001024.504861.6448AID743215
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency54.941019.739145.978464.9432AID1159509
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency21.68990.000323.4451159.6830AID743065
heat shock protein beta-1Homo sapiens (human)Potency61.64480.042027.378961.6448AID743210
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (33.33)18.2507
2000's2 (22.22)29.6817
2010's3 (33.33)24.3611
2020's1 (11.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.39

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.39 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.69 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.39)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (11.11%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (88.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]